GlassScriptPhysician profile
Sienna Collins
NPI 1467090829
$3,855.72
in general payments reported to CMS, 2019-2025
54 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $316 · 2023: $674 · 2024: $1,193 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.00 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $311.99 | 2021-2024 | Padcev, Xtandi |
| Janssen Biotech, INC. | $265.57 | 2022-2025 | Rybrevant, Carvykti, Talvey |
| Eisai INC. | $221.71 | 2022-2025 | |
| Incyte Corporation | $205.45 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| E.R. Squibb & Sons, L.L.C. | $190.83 | 2022-2025 | Opdivo, Opdualag, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $178.27 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Pfizer INC. | $173.64 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $172.72 | 2022-2025 | Keytruda, Reblozyl |
| Novartis Pharmaceuticals Corporation | $148.86 | 2023-2025 | |
| Abbvie INC. | $147.80 | 2023-2025 | |
| Genzyme Corporation | $142.52 | 2022-2025 | |
| Lilly USA, LLC | $138.68 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $98.21 | 2024-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.58 | 2023-2025 | Gilotrif |
| Astrazeneca Pharmaceuticals LP | $83.42 | 2023-2025 | Imfinzi, Calquence, Lynparza |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $79.62 | 2022-2025 | Reblozyl, Pomalyst |
| Caris Mpi, INC. | $73.80 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $71.85 | 2024-2025 | Monoferric, Cosela |
| Deciphera Pharmaceuticals INC. | $62.98 | 2024-2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $62.06 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.76 | 2022-2025 | |
| Stryker Corporation | $51.50 | 2025 | Optablate |
| Beone Medicines USA, INC. | $49.73 | 2025 | Tevimbra, Brukinsa |
| Genmab U.S., INC. | $47.62 | 2024-2025 | Tivdak |
| Aveo Pharmaceuticals, INC. | $46.67 | 2023-2025 | Fotivda |
| Gilead Sciences, INC. | $46.19 | 2023-2024 | |
| Daiichi Sankyo INC. | $42.82 | 2025 | Enhertu, Datroway |
| Mirati Therapeutics, INC. | $41.05 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $37.09 | 2025 | Onivyde |
| Genentech USA, INC. | $36.78 | 2025 | Tecentriq, Venclexta |
| Janssen Pharmaceuticals, INC | $34.81 | 2023-2024 | Xarelto |
| Array Biopharma INC | $31.82 | 2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $29.26 | 2023 | Imbruvica |
| Exelixis INC. | $27.37 | 2025 | Cabometyx |
| Organon LLC | $23.71 | 2024 | |
| Beigene USA, INC. | $23.22 | 2023 | Brukinsa |
| Adc Therapeutics America, INC. | $21.43 | 2025 | |
| Blueprint Medicines Corporation | $21.18 | 2022 | |
| Spectrum Pharmaceuticals INC. | $20.72 | 2025 | Rolvedon |
| Karyopharm Therapeutics INC. | $20.69 | 2024 | Xpovio |
| Glaxosmithkline, LLC. | $20.45 | 2023 | Jemperli |
| Emd Serono, INC. | $19.84 | 2024 | |
| Adaptive Biotechnologies Corporation | $18.70 | 2024 | Clonoseq |
| Apellis Pharmaceuticals, INC. | $18.62 | 2023 | Empaveli |
| Kyowa Kirin, INC. | $16.88 | 2024 | Poteligeo |
| Stemline Therapeutics INC. | $16.26 | 2023 | Orserdu |
| Amneal Pharmaceuticals LLC | $16.21 | 2023 | Avastin, Neupogen, Neulasta |
| Novocure INC. | $15.72 | 2025 | Optune Lua (Novottf-200t) |
| Cti Biopharma Corp. | $15.41 | 2023 | Vonjo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.16 | 2022 | |
| Seagen INC. | $14.95 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.94 | 2024 | |
| Pharmaand Gmbh | $14.80 | 2025 | Rubraca |
| Tolmar, INC. | $14.80 | 2025 | Eligard, Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sienna Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.